SCIENTIFIC HUB

Araştırmanın izini sürün.

SCIENTIFIC LITERATURE · MED

Comparative Efficacy and Safety of Treatments for Parkinson's Disease With Depression: A Systematic Review and Bayesian Model-Based Network Meta-Analysis.

Brain Behav · 2026-08-01

DOI: 10.1002/brb3.71722PMID: 42642880

Open accessSystematic Review; review-article; Review; Network Meta-Analysis; Journal ArticleKaynağa git ↗

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

ObjectiveDepression is a common non-motor symptom of Parkinson's disease (PD) and substantially impairs patients' quality of life. This study aimed to compare the efficacy and safety of different interventions for depression in PD.MethodsWe conducted a systematic review and Bayesian network meta-analysis of randomized controlled trials (RCTs) in patients with PD and depression. Databases were searched from inception to September 30, 2025. Treatment effects were estimated using standardized mean differences (SMDs) for efficacy and odds ratios (ORs) for safety. Surface Under the Cumulative Ranking Curve (SUCRA) values were used to rank interventions. The protocol was registered in PROSPERO (CRD420251245403).ResultsThis study included 51 RCTs involving 5100 patients and 42 intervention measures. Compared with placebo, citalopram (SMD = -0.99, 95% CI: -1.87 to -0.12) and primary motor cortex (M1) repetitive transcranial magnetic stimulation (rTMS) (SMD = -1.29, 95% CI: -1.93 to -0.64) significantly improved depressive symptoms with moderate-quality evidence. SUCRA rankings favored citalopram (0.831), M1 rTMS (0.825), pergolide (0.811), and supplementary motor area (SMA) + M1 rTMS (0.802), although rankings should be interpreted alongside direct statistical comparisons. Several treatments could not be included in the safety network because of insufficient connectivity. Citalopram, sertraline, rasagiline, methylphenidate, memantine, and trazodone were associated with higher withdrawal rates due to adverse events.ConclusionOur findings indicate that selective serotonin reuptake inhibitors (SSRIs), dopamine agonists, and rTMS suggest relative efficacy and an acceptable safety profile in treating PD with depression. However, given the limited evidence for several interventions, these findings should be interpreted cautiously and confirmed in larger, multicenter studies.

Bilimsel değerlendirme

01

Araştırma sorusu

Sorunun kapsamı orijinal çalışma üzerinden değerlendirilir.

02

Yöntem ve örneklem

Çalışma tasarımı ve örneklem için kaynak makaleyi kontrol edin.

03

Temel bulgular

Bu kayıt için editoryal olarak onaylanmış bulgu özeti henüz yayımlanmadı.

04

Sınırlılıklar

Sonuçların genellenebilirliği, yanlılık ve klinik anlamı ayrıca incelenmelidir.

Bibliyografik veriden yöntem, örneklem veya klinik sonuç çıkarımı yapılmaz.